PE99699A1 - Composicion que comprende un inhibidor selectivo de la reabsorcion de serotonina y un �-bloqueante - Google Patents

Composicion que comprende un inhibidor selectivo de la reabsorcion de serotonina y un �-bloqueante

Info

Publication number
PE99699A1
PE99699A1 PE1998000612A PE00061298A PE99699A1 PE 99699 A1 PE99699 A1 PE 99699A1 PE 1998000612 A PE1998000612 A PE 1998000612A PE 00061298 A PE00061298 A PE 00061298A PE 99699 A1 PE99699 A1 PE 99699A1
Authority
PE
Peru
Prior art keywords
selective inhibitor
blocker
composition including
serotonin reabsorption
composition
Prior art date
Application number
PE1998000612A
Other languages
English (en)
Inventor
Paul John Cummings
Ian Frederic Tulloch
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of PE99699A1 publication Critical patent/PE99699A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UNA COMPOSICION QUE COMPRENDE a)UN INHIBIDOR SELECTIVO DE LA REABSORCION DE SEROTONINA DE RAPIDA LIBERACION (SSRI), SIENDO DE PREFERENCIA HIDROCLORURO DE PAROXETINA (20 mg) Y b)UN �-BLOQUEANTE QUE SE LIBERA EN FORMA SOSTENIDA, SIENDO DE PREFERENCIA PINDOLOL O SU ISOMERO (7,5 mg). TAMBIEN SE REFIERE A LA FORMA DE PRESENTACION COMO COMPRIMIDO DE DOS CAPAS, UNA DE LAS CUALES CONTIENE HIDROCLORURO DE PAROXETINA Y LA OTRA CAPA CONTIENE PINDOLOL. LA COMPOSICION PUEDE SER UTIL PARA TRATAR ALCOHOLISMO, ANSIEDAD, DEPRESION, TRASTORNO OBSESIVO COMPULSIVO (OCD), TRASTORNO DEL PANICO, DOLOR CRONICO, OBESIDAD, DEMENCIA SENIL, MIGRANA
PE1998000612A 1997-07-11 1998-07-10 Composicion que comprende un inhibidor selectivo de la reabsorcion de serotonina y un �-bloqueante PE99699A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9714675.7A GB9714675D0 (en) 1997-07-11 1997-07-11 Novel composition

Publications (1)

Publication Number Publication Date
PE99699A1 true PE99699A1 (es) 1999-12-21

Family

ID=10815744

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000612A PE99699A1 (es) 1997-07-11 1998-07-10 Composicion que comprende un inhibidor selectivo de la reabsorcion de serotonina y un �-bloqueante

Country Status (26)

Country Link
EP (1) EP0996466A2 (es)
JP (1) JP2002508003A (es)
KR (1) KR20010021644A (es)
CN (1) CN1262627A (es)
AP (1) AP2000001728A0 (es)
AR (1) AR016128A1 (es)
AU (1) AU9340198A (es)
BG (1) BG104119A (es)
BR (1) BR9810996A (es)
CA (1) CA2295822A1 (es)
CO (1) CO4950552A1 (es)
DZ (1) DZ2556A1 (es)
EA (1) EA200000112A1 (es)
GB (1) GB9714675D0 (es)
HU (1) HUP0003074A3 (es)
ID (1) ID24191A (es)
IL (1) IL133869A0 (es)
MA (1) MA24604A1 (es)
NO (1) NO20000107L (es)
OA (1) OA11276A (es)
PE (1) PE99699A1 (es)
PL (1) PL338017A1 (es)
SK (1) SK72000A3 (es)
TR (1) TR200000074T2 (es)
WO (1) WO1999002142A2 (es)
ZA (1) ZA986138B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1121111E (pt) 1998-10-15 2010-05-17 Imp Innovations Ltd Compostos para o tratamento de perda de peso
ID29852A (id) 1998-11-02 2001-10-18 Elan Corp Plc Cs Komposisi pelepasan modifikasi multi partikulasi
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
AU764453B2 (en) 1999-10-29 2003-08-21 Euro-Celtique S.A. Controlled release hydrocodone formulations
GB0004003D0 (en) * 2000-02-22 2000-04-12 Knoll Ag Therapeutic agents
CN101317825A (zh) 2000-10-30 2008-12-10 欧罗赛铁克股份有限公司 控释氢可酮制剂
AU2005283829A1 (en) * 2004-09-17 2006-03-23 Neurocure Ltd Pindolol for the treating premenstrual syndrome and premenstrual dysphoric disorder
CN100469356C (zh) * 2006-09-08 2009-03-18 山东益康药业有限公司 复方阿替洛尔缓释片及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2732335C2 (de) * 1976-07-27 1983-01-20 Sandoz-Patent-GmbH, 7850 Lörrach Tablette zur enteralen Verabreichung von Indolyloxyalkanolamin-Derivaten
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
ES2145977T3 (es) * 1995-08-16 2000-07-16 Lilly Co Eli Potenciacion de la respuesta de la serotonina.
EP0792649A1 (en) * 1996-02-29 1997-09-03 Eli Lilly And Company Treatment of sleep disorders

Also Published As

Publication number Publication date
CO4950552A1 (es) 2000-09-01
NO20000107D0 (no) 2000-01-10
OA11276A (en) 2003-07-31
CA2295822A1 (en) 1999-01-21
EA200000112A1 (ru) 2000-10-30
GB9714675D0 (en) 1997-09-17
EP0996466A2 (en) 2000-05-03
WO1999002142A3 (en) 1999-04-15
AU9340198A (en) 1999-02-08
HUP0003074A2 (hu) 2001-01-29
BG104119A (en) 2000-12-29
IL133869A0 (en) 2001-04-30
MA24604A1 (fr) 1999-04-01
ZA986138B (en) 2000-01-10
JP2002508003A (ja) 2002-03-12
ID24191A (id) 2000-07-13
NO20000107L (no) 2000-01-10
AR016128A1 (es) 2001-06-20
AP2000001728A0 (en) 2000-03-31
HUP0003074A3 (en) 2001-12-28
SK72000A3 (en) 2000-12-11
TR200000074T2 (tr) 2000-05-22
WO1999002142A2 (en) 1999-01-21
CN1262627A (zh) 2000-08-09
DZ2556A1 (fr) 2003-02-15
KR20010021644A (ko) 2001-03-15
BR9810996A (pt) 2000-08-08
PL338017A1 (en) 2000-09-25

Similar Documents

Publication Publication Date Title
CO4900058A1 (es) Terapia de combinacion para el tratamiento de psicosis
PE99699A1 (es) Composicion que comprende un inhibidor selectivo de la reabsorcion de serotonina y un �-bloqueante
ECSP067070A (es) Compuestos y composiciones como inhibidores de la proteína quinasa
ES2172744T3 (es) Composiciones farmaceuticas que comprenden mirtazapina y uno o varios inhibidores selectivos de asimilacion de serotonina.
ECSP055885A (es) Derivados de carbostirilo e inhibidores de la recaptacion de serotonina que sirven para el tratamiento de desordenes en el humor
BR0008958A (pt) Inibidores de reabsorção de monoamina para otratamento de distúrbios do snc
JP2005532372A5 (es)
NO20054228L (no) Anvendelse av (IS,2R)-enantiomeren av milnacipran for fremstillingen av et medikament
ZA200509542B (en) Combination of an NDMA receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders
ES2153410T3 (es) Elemento aislante de pared, piso o fachada y sistema para renovacion de aire.
CL2007001584A1 (es) Composicion farmaceutica que comprende: un nucleo con fenilefrina en forma de liberacion inmediata y una capa erosionable que comprende fenilefrina y una matriz de liberacion sostenida; util para tratar los sintomas del resfriado, influenza, alergias o rinitis no alergicas.
NO20053088L (no) Farmasoytisk preparat inneholdende en beta-3-adrenoseptoragonist og en serotonin og/eller norepinefrin-gjenopptakelsesinhibitor og anvendelse av nevnte preparat for behandling av blaeredysfunksjon.
MX2007000009A (es) Forma farmaceutica oral, protegida frente al abuso.
ATE319464T1 (de) Diätetische nahrungsergänzung zur unterstützung des zerebrovaskulären tonus
AR033748A1 (es) Un dispositivo para la administracion transdermica de sustancias farmacologicamente activas que comprende dos capas adhesivas superpuestas y un procedimiento para prepararlo
BRPI0411665A (pt) uso de agomelatina ou de um seu sal farmaceuticamente aceitável, composição farmacêutica ou kit, e, métodos para o tratamento de doenças ou distúrbios responsivos a um inibidor da recaptação de serotonina e para aumentar e/ou proporcionar inìcio mais rápido do efeito terapêutico de um inibidor da recaptação de serotonina
De Witte Encountering religion through Accra's urban soundscape
Murphy et al. Chronic exposure of rats to cognition enhancing drugs produces a neuroplastic response identical to that obtained by complex environment rearing
Kanbayashi et al. Effects of donepezil (Aricept) on the rapid eye movement sleep of normal subjects
AR017884A1 (es) Proceso para preparar una composicion farmaceutica que comprende zafirlukast, dicha composicion farmaceutica y metodo para tratar pacientes usando lacomposicion
JP2007505156A5 (es)
Nishio et al. Role of the lipoxygenase pathway in phenylephrine-induced vascular smooth muscle cell proliferation and migration
RS51669B (en) NEW DRUG COMBINATIONS AS ANTIDEPRESSIVE
SG154337A1 (en) Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
Muessig Medieval Preaching

Legal Events

Date Code Title Description
FC Refusal